The trial was a comparison of the first such medicine, Wegovy (also known as semaglutide, or Ozempic when used for type 2 diabetes) with recent arrival Mounjaro (tirzepatide). Mounjaro caused the most weight loss.
But the direct comparison was necessary, because the past trials could have had subtle differences that wrongly made one medicine look better than the other – for instance, the participants could have had more health complications. The head-to-head has confirmed that Mounjaro leads to more weight loss when all else is equal.
square NEWS AnalysisTeenagers given weight loss jabs on the NHS as obesity crisis grows
Read More
After about one year of use, people taking Mounjaro had lost 20 per cent of their initial weight. People taking Wegovy had lost about 14 per cent.
Who needs to take Mounjaro?
People who are very obese may need Mounjaro to reach a healthy weight, said Dr Aronne. “It may be that people at a higher body mass index may do better with a more potent [drug].”
Mounjaro, on the other hand, mimics both GLP-1 and a second hormone called GIP, so it is less of a known quantity. “People that are really worried about longer-term outcomes can say [Wegovy] is a perfect drug for me,” said Professor Le Roux. “People who need more weight loss, might feel [Mounjaro] is perfect.”
Wegovy has revolutionised weight loss treatment (Photo: Tatsiana Volkava/ Getty Images/ Moment RF)Do the drugs have different effects on health?
“For cardiologists, for people who’ve had [heart attacks] they are focused on semaglutide,” said Dr Aronne. Health insurance companies may be willing to cover the cost of Wegovy but not Mounjaro.
The trial was run by Eli Lilly, manufacturer of Mounjaro. “These data confirm [Mounjaro] as an important treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan,” said Leonard Glass, Eli Lilly’s senior vice president of global medical affairs.
“We believe that treating obesity is about more than just a number on a scale and Wegovy is the only GLP-1 obesity medication approved to prevent major cardiovascular events such as cardiovascular death, heart attack, and stroke and thereby potentially save and prolong lives.”
Do other weight loss injections have different benefits?
For instance, some drugs seem to be especially helpful for people with fatty liver disease, while others help people keep their muscle while losing fat tissue. Those would be helpful for older people where loss of muscle is a concern, he said.
Read More Details
Finally We wish PressBee provided you with enough information of ( Why you might be given the ‘second-best’ weight loss drug )
Also on site :